Structure Therapeutics Inc. American Depositary Shares
GPCR
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Last trade$18.21
Day change-$0.365 (-1.97%)
Day range$17.87 – $19.45
Volume347,320
Market cap$1.33B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.33B
Price / earnings
—
Price / book
1.09×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.17×
Profitability
Earnings per share
-$4.11
Return on assets
-22.02%
Return on equity
-24.05%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.91×
Quick ratio
11.91×
Cash ratio
2.07×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$277.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GPCR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$21.78M
$18.57M
$22.87M
$17.57M
$14.8M
$15.74M
$13.44M
$13.57M
Research and development
$134.55M
$100.06M
$66.51M
$68.69M
$58.99M
$54.71M
$42.87M
$33.49M
Total operating expenses
$156.33M
$118.63M
$89.38M
-$13.74M
$73.79M
$70.45M
$56.31M
$47.06M
Operating income
-$156.33M
-$118.63M
-$89.38M
$13.74M
-$73.79M
-$70.45M
-$56.31M
-$47.06M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$144.59M
-$105.93M
-$75.78M
$33.17M
-$65.6M
-$61.52M
-$46.74M
-$36.34M
Income taxes
$171K
$234K
$190K
$170K
$108K
$139K
$98K
$136K
Net income
-$144.76M
-$106.16M
-$75.97M
$33M
-$65.71M
-$61.66M
-$46.83M
-$36.48M
Net income attributable to common shareholders
-$144.76M
-$106.16M
-$75.97M
$33M
-$65.71M
-$61.66M
-$46.83M
-$36.48M
EBITDA
-$156.27M
-$118.08M
-$88.8M
$14.15M
-$73.43M
-$70.16M
-$56.04M
-$46.79M
Basic earnings per share
-$0.66
-$0.49
-$0.35
$0.17
-$0.37
-$0.36
-$0.27
-$0.21
Diluted earnings per share
-$0.66
-$0.49
-$0.35
$0.17
-$0.37
-$0.36
-$0.27
-$0.21
Recent news
Company coverage with links to the original publishers.
Novo's newly launched Wegovy oral pill generated DKK 5.4 billion in Q3 2026 sales with 3.6 million U.S. prescriptions, prompting the company to raise its 2026 growth outlook. However, the company faces intense competition from Eli Lilly's surging Mounjaro and Zepbound sales, as well as emerging competitors like Viking Therapeutics and Structure Therapeutics developing alternative GLP-1 therapies. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation.
Novo Nordisk shares gained 4.3% over the past month following better-than-expected Q3 results and raised 2026 guidance, driven by strong Wegovy pill sales exceeding 8 million U.S. prescriptions. However, the company faces significant headwinds from Eli Lilly's growing obesity drug presence, pricing pressures on injectable products, and pipeline setbacks. While long-term investors may hold positions given the company's established obesity franchise and pipeline potential, short-term investors should await greater visibility on sustainable growth and market-share stabilization.
Novo Nordisk is expected to report Q3 2026 earnings on November 4 with revenues estimated at $11.39 billion and EPS at 81 cents. The company faces significant headwinds from intensifying competition in the GLP-1 market, particularly from Eli Lilly's tirzepatide-based therapies, pricing pressure, and reduced Medicaid coverage. While oral Wegovy and Ozempic launches offer growth opportunities, Novo's 2026 outlook remains challenged with expected flat to 6% sales decline. Analysts recommend investors remain on the sidelines ahead of earnings.
Novo Nordisk's Q3 2026 results will focus on Ozempic and Wegovy sales, which represent 75.5% of H1 adjusted sales. The company faces pricing pressure, weaker injectable GLP-1 prescription trends, and intensifying competition from Eli Lilly's tirzepatide drugs. Novo's oral semaglutide pills (Wegovy and Ozempic tablets) show strong early uptake, but overall 2026 guidance remains flat to -6% at constant exchange rates.
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, up 88% year-over-year, accounting for 65% of total revenues. The company's newly launched oral obesity therapy Foundayo posted $98 million in Q2 sales with expanding coverage. Lilly faces competition from Novo Nordisk's semaglutide drugs and emerging biotech firms developing alternative GLP-1 therapies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.